Summary
Thermo Fisher Scientific Inc. (TMO) issued a Current Report (8-K) on May 13, 2020, providing an update on its expected second quarter 2020 organic revenue growth. The company revised its guidance to a range of flat to negative 10% organic revenue growth, an improvement from the previously provided range of flat to negative 15% announced on April 22, 2020. This adjustment reflects the company's current perspective on the impact of the COVID-19 pandemic. While the revised outlook indicates a potentially less severe revenue impact than initially feared for the second quarter, investors should note that actual results could still fall outside this updated range due to ongoing significant market uncertainty. The company also made reference to a virtual fireside chat where its CEO, Marc N. Casper, discussed these matters. The filing reiterates forward-looking statements are subject to various risks and uncertainties, including the duration and severity of the COVID-19 pandemic.
Key Highlights
- 1Thermo Fisher updated its Q2 2020 organic revenue growth outlook to flat to negative 10%, an improvement from the prior guidance of flat to negative 15%.
- 2The company attributes this updated outlook to its current perspective on the impact of the COVID-19 pandemic.
- 3This update was discussed by CEO Marc N. Casper during a virtual fireside chat at the BofA Securities 2020 Health Care Conference.
- 4Significant market uncertainty persists, and actual Q2 results could still fall outside the revised range.
- 5The filing includes standard cautionary statements regarding forward-looking statements and associated risks, including the COVID-19 pandemic's evolving impact.
- 6The company continues to monitor and adapt to the evolving global health situation and its business implications.